|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
|
24952855 |
2014 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials.
|
27287251 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Update on primary PCI for patients with STEMI.
|
27450063 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased PLR levels are independently associated with a greater risk of CI-AKI in patients undergoing primary PCI for STEMI.
|
27473864 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite primary PCI being the well-established therapy, there are rooms for further research to optimize STEMI outcomes.
|
27846459 |
2017 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Low risk patients identified using CADILLAC risk score with STEMI treated successfully with primary PCI have a low adverse event rate on the third day or later of hospitalization suggesting that an earlier discharge is safe in properly selected patients.
|
27896906 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, prasugrel and ticagrelor decreased the risk of all-cause death, major adverse cardiac events, and stent thrombosis without causing more bleeding events compared with clopidogrel in patients with STEMI undergoing PCI.
|
28045759 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the same time period, eight consecutive patients with large anterior STEMI who received primary PCI but not HT were included as control group.
|
28087172 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The influence of polymorphisms in the large group of MMP and TIMP genes on clinical outcomes in patients after ST elevation myocardial infarction (STEMI) treated with primary PCI was analysed.
|
28101856 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
From 2007 to 2014, 1,525 consecutive patients (79% men, mean age 61 years) who underwent primary percutaneous coronary intervention for STEMI in the INTERSTELLAR (Incheon-Bucheon Cohort of Patients Undergoing Primary PCI for Acute ST-Elevation Myocardial Infarction) cohort were analyzed retrospectively.
|
28214004 |
2017 |
|
SERPINA5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Door-to-balloon (DTB) time ≤90 min is an important quality indicator in the management of ST-elevation myocardial infarction (STEMI), but a considerable number of patients still do not meet this goal, particularly in countries outside the USA and Europe.Methods and Results:We analyzed 2,428 STEMI patients who underwent primary PCI ≤12 h of symptom onset who were registered in an ongoing prospective multicenter database (JCD-KiCS registry), between 2008 and 2013.
|
28228609 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
|
28230176 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of point-of-care pre-procedure creatinine and eGFR testing in patients with ST segment elevation myocardial infarction undergoing primary PCI: The pilot STATCREAT study.
|
28400120 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the DANAMI-3-PRIMULTI study (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization), we randomized 627 ST-segment-elevation myocardial infarction patients to fractional flow reserve-guided complete revascularization or infarct-related percutaneous coronary intervention only.
|
28404623 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients in group 1 underwent elective angioplasty and stenting, whereas all patients included in groups 2 and 3 suffered from acute coronary syndromes (STEMI or NSTEMI) and underwent urgent PCI.
|
28425039 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with STEMI and LV dysfunction doxycycline can favorably modulate the LV filling pattern early after primary PCI.
|
28433557 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fewer diabetic patients met first medical contact to PCI time for STEMI (44% vs 52%).
|
28454811 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emergent or urgent CABG for treatment of acute coronary complications following PCI is feasible and has acceptable clinical results that worsen in the presence of STEMI, cardiogenic shock, or resuscitation.
|
28457342 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Numbers of PCIs have risen by 15% over the last four years, coinciding with an increase in the number of cathlabs by 50%, aiming at better access to primary PCI for STEMI patients.
|
28504223 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The records were reviewed for patients admitted to the large comprehensive university hospital for PCI due to STEMI from January 1, 2002 to January 1, 2017.
|
28511806 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reloaded patients were younger, had fewer comorbid conditions, and were more likely to be treated with primary PCI (STEMI) or an early invasive strategy (NSTEMI).
|
28541452 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Use of the CADILLIAC Risk Score can accurately identify patients for safe early discharge after PCI for STEMI.
|
28612413 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
During hospitalization, Patients in prior BBs group were more likely to develop decompensated heart failure (9.9% vs. 3.6%, P<0.001), less likely to have STEMI (33.9% vs. 54.4%, P<0.001), and subsequently less PCI (73.2% vs. 81.3%, P=0.002), but higher inpatient mortality (8.8% vs. 4.8%, P=0.009).
|
28747039 |
2017 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients presenting to the Alfred Hospital, a tertiary referral hospital, between 1 January 2010 and 31 December 2015 undergoing PCI for STEMI were identified.
|
28797607 |
2018 |
|
SERPINA5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased hs-CRP levels at presentation are associated with impaired microvascular reperfusion after PCI in STEMI patients and remain higher until 2months follow-up.
|
28826799 |
2017 |